Finance

Lists
Outlook: 58.8% bullish·14.7% bearish
Go to analysis
UTHR:NASDAQ
United Therapeutics Corp
$545.00
+0.62%
(+3.38) 1D
$545.00
0.00% (0.00)
After hours
Closed: Oct 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for UTHR...
Open
$542.41
High
$558.30
Low
$541.90
Mkt. cap
23.38B
Avg. vol.
851.89K
Volume
1.01M
P/E ratio
19.49
52-wk high
$609.35
52-wk low
$409.15
EPS
$27.96
Beta
0.49
Shares outstanding
42.89M
No. of employees
1K
Open
$542.41
High
$558.30
Low
$541.90
Mkt. cap
23.38B
Avg. vol.
851.89K
Volume
1.01M
P/E ratio
19.49
52-wk high
$609.35
52-wk low
$409.15
EPS
$27.96
Beta
0.49
Shares outstanding
42.89M
No. of employees
1K
News stories
From web sources and news partners
Profile
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. Wikipedia
About United Therapeutics Corp
CEO-
Employees1.4K
Founded1996
HeadquartersSilver Spring, Maryland, United States
SectorBiotechnology
Websiteunither.com
Analyst ratings
Based on 12 analysts giving stock ratings to UTHR in the past 3 months
Buy
Buy
9
Hold
2
Sell
1
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for UTHR in the last 3 months.
Highest
Current $545.00
$728.00 (+33.58%)
Average
$643.00 (+17.98%)
Lowest
$321.00 (-41.10%)
Analyst
Recommendation
Action
Price target
Projected
Date
Terence Flynn
Morgan Stanley
Hold
Reiterated
$566.00
+3.9%
10/07/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
$685.00
+25.7%
10/01/2026
Roger Song
Jefferies
Buy
Maintained
$704.00
+29.2%
10/01/2026
Julian Harrison
BTIG
Buy
Upgraded
$728.00
+33.6%
10/01/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Initiated
$700.00
+28.4%
09/30/2026
Lisa Walter
RBC Capital
Buy
Reiterated
$677.00
+24.2%
09/30/2026
Andrea Newkirk
Goldman Sachs
Sell
Initiated
$321.00
-41.1%
09/24/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$700.00
+28.4%
09/02/2026
Joseph Thome
TD Cowen
Buy
Maintained
$675.00
+23.9%
09/02/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$660.00
+21.1%
08/06/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
$687.00
+26.1%
07/23/2026
Jason Gerberry
Bank of America Securities
Hold
Reiterated
$613.00
+12.5%
07/10/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$685.00
+25.7%
05/20/2026
Unknown Analyst
Raymond James
Buy
Initiated
$700.00
+28.4%
04/09/2026
Tiago Fauth
Raymond James
Buy
Initiated
$700.00
+28.4%
04/09/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
$650.00
+19.3%
03/12/2026
Ashwani Verma
UBS
Buy
Reiterated
$705.00
+29.4%
03/05/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
$560.00
+2.8%
03/03/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
$7.27 / $7.03
+3.47%beat
Revenue / Est. (USD)
783.30M / 804.65M
-2.65%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
799.50M
790.20M
781.50M
783.30M
Cost of goods sold
100.90M
103.40M
133.40M
99.50M
Cost of revenue
100.90M
103.40M
133.40M
99.50M
Research and development expenses
127.50M
139.50M
138.20M
146.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
181.80M
189.90M
184.10M
206.70M
Operating expense
309.30M
329.40M
322.30M
353.00M
Total operating expenses
410.20M
432.80M
455.70M
452.50M
Operating income
389.30M
357.40M
325.80M
330.80M
Other non operating income
300.00K
800.00K
15.30M
-100.00K
EBT including unusual items
438.00M
444.00M
318.30M
372.70M
EBT excluding unusual items
433.00M
398.30M
379.90M
359.30M
Income tax expense
99.30M
79.70M
43.40M
39.70M
Effective tax rate
22.67%
17.95%
13.63%
10.65%
Other operating expenses
-
-
-
-
Net income
338.70M
364.30M
274.90M
333.00M
Net profit margin
42.36%
46.10%
35.18%
42.51%
Earnings per share
7.16
7.70
5.82
7.27
Interest and investment income
46.40M
43.20M
41.80M
31.50M
Interest expense
-3.00M
-3.10M
-3.00M
-2.90M
Net interest expenses
43.40M
40.10M
38.80M
28.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
411.20M
380.20M
348.40M
355.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps